School of Optometry and Vision Science Program, University of California Berkeley, Berkeley, California, United States.
Invest Ophthalmol Vis Sci. 2018 May 1;59(6):2644-2651. doi: 10.1167/iovs.17-22890.
To determine whether latanoprost, a prostaglandin analog proven to be very effective in reducing intraocular pressure (IOP) in humans, can also slow myopia progression in the guinea pig form deprivation (FD) model.
Two-week-old pigmented guinea pigs underwent monocular FD and daily topical latanoprost (0.005%, n = 10) or artificial tears (control, n = 10) starting 1 week after the initiation of FD, with all treatments continuing for a further 9 weeks. Tonometry, retinoscopy, and high-frequency A-scan ultrasonography were used to monitor IOP, refractive error, and ocular axial dimensions, respectively.
Latanoprost significantly reduced IOP and slowed myopia progression. Mean interocular IOP differences (±SEM) recorded at baseline and week 10 were -0.30 ± 0.51 and 1.80 ± 1.16 mm Hg (P = 0.525) for the control group and 0.07 ± 0.35 and -5.17 ± 0.96 mm Hg (P < 0.001) for the latanoprost group. Equivalent interocular differences for optical axial length at baseline and week 10 were 0.00 ± 0.015 and 0.29 ± 0.04 mm (P < 0.001; control) and 0.02 ± 0.02 and 0.06 ± 0.02 mm (P = 0.202; latanoprost), and for refractive error were +0.025 ± 0.36 and -8.2 ± 0.71 diopter (D) (P < 0.001; control), and -0.15 ± 0.35 and -2.25 ± 0.54 D (P = 0.03; latanoprost).
In the FD guinea pig model, latanoprost significantly reduces the development of myopia. Although further investigations into underlying mechanisms are needed, the results open the exciting possibility of a new line of myopia control therapy.
确定前列腺素类似物拉坦前列素是否能减缓豚鼠形剥夺模型的近视进展，该类似物已被证明能有效降低人类眼内压（IOP）。
2 周龄有色豚鼠行单眼形剥夺，并于形剥夺开始后 1 周开始每天局部使用拉坦前列素（0.005%，n = 10）或人工泪液（对照组，n = 10），所有治疗均进一步持续 9 周。眼压计、检影镜和高频 A 型超声检查分别用于监测眼压、屈光不正和眼轴。
拉坦前列素显著降低眼压并减缓近视进展。对照组在基线和第 10 周记录的双眼间眼压差异（±SEM）分别为-0.30 ± 0.51 和 1.80 ± 1.16 mmHg（P = 0.525），而拉坦前列素组分别为 0.07 ± 0.35 和-5.17 ± 0.96 mmHg（P < 0.001）。基线和第 10 周双眼间眼轴等效差异分别为 0.00 ± 0.015 和 0.29 ± 0.04 mm（P < 0.001；对照组）和 0.02 ± 0.02 和 0.06 ± 0.02 mm（P = 0.202；拉坦前列素组），而屈光不正差异分别为+0.025 ± 0.36 和-8.2 ± 0.71 屈光度（D）（P < 0.001；对照组）和-0.15 ± 0.35 和-2.25 ± 0.54 D（P = 0.03；拉坦前列素组）。
在形剥夺豚鼠模型中，拉坦前列素可显著减缓近视的发展。尽管需要进一步研究其潜在机制，但结果为新的近视控制疗法开辟了令人兴奋的可能性。
